Second Sight to Present at the Rodman & Renshaw 18th Annual Global Investment Conference on September 13, 2016
September 02 2016 - 8:00AM
Business Wire
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second
Sight" or "the Company"), a developer, manufacturer and marketer of
implantable visual prosthetics to provide some useful vision to
blind patients, will present at the Rodman & Renshaw 18th
Annual Global Investment Conference being held September 11-13,
2016.
Second Sight’s Chairman, Dr. Robert Greenberg, will host
one-on-one meetings throughout the day on Monday, September 12,
2016 and Tuesday, September 13, 2016, and is scheduled to present
as follows:
Date: Tuesday, September 13, 2016 Time: 11:15 a.m.
Eastern time Location: Lotte New York Palace Hotel, New York in
Kennedy I (4th Floor)
The presentation will be webcast live at the aforementioned time
as well as archived for 90 days thereafter at
http://wsw.com/webcast/rrshq26/eyes, or via the Company's website
at www.secondsight.com, under the Investors Section.
About the Argus® II Retinal Prosthesis System
Second Sight's Argus II System provides electrical stimulation
that bypasses the defunct retinal cells and stimulates remaining
viable cells inducing visual perception in individuals with severe
to profound outer retinal degeneration such as retinitis pigmentosa
(RP). The Argus II works by converting images captured by a
miniature video camera mounted on the patient's glasses into a
series of small electrical pulses, which are transmitted wirelessly
to an array of electrodes implanted on the surface of the retina.
These pulses are intended to stimulate the retina's remaining
cells, resulting in the perception of patterns of light in the
brain. The patient then learns to interpret these visual patterns,
thereby regaining some useful vision. The system is controlled by
software and is upgradeable, which may provide improved performance
as new algorithms are developed and tested. Therefore current and
future Argus II users may benefit from the continuously improving
technology. The Argus II is the first artificial retina to receive
widespread approval, and is offered at approved centers in Austria,
Canada, France, Germany, Italy, Netherlands, Saudi Arabia, Spain,
Switzerland, Turkey, United Kingdom and the United States.
About Second Sight
Second Sight's mission is to develop, manufacture and market
innovative implantable visual prosthetics to enable blind
individuals to achieve greater independence. Second Sight has
developed and now manufactures and markets the Argus® II Retinal
Prosthesis System. Enrollment has been completed in a feasibility
trial to test the safety and utility of the Argus II in individuals
with Dry Age-Related Macular Degeneration. Second Sight is also
developing the Orion™ I Visual Cortical Prosthesis to restore
some vision to individuals who are blind due to causes other than
preventable or treatable conditions. U.S. Headquarters
are in Sylmar, California, and European Headquarters are in
Lausanne, Switzerland. For more information,
visit www.secondsight.com.
Safe Harbor
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange and Exchange
Act of 1934, as amended, which are intended to be covered by the
"safe harbor" created by those sections. All statements in this
release that are not based on historical fact are "forward looking
statements." These statements may be identified by words such as
"estimates," "anticipates," "projects," "plans," or "planned,"
"seeks," "may," "will," "expects," "intends," "believes," "should,"
"potentially," "objectives," and similar expressions or the
negative versions thereof and which also may be identified by their
context. While management has based any forward looking statements
included in this release on its current expectations, the
information on which such expectations were based may change.
Forward-looking statements involve inherent risks and uncertainties
which could cause actual results to differ materially from those in
the forward-looking statements, as a result of various factors
including those risks and uncertainties described in the Risk
Factors and in Management's Discussion and Analysis of Financial
Condition and Results of Operations sections of the Company's
Annual Report on Form 10-K as filed on March 11, 2016 and the
Company's other reports filed from time to time with
the Securities and Exchange Commission. We urge you to
consider those risks and uncertainties in evaluating the Company's
forward-looking statements. We caution readers not to place undue
reliance upon any such forward-looking statements, which speak only
as of the date made. Except as otherwise required by the federal
securities laws, we disclaim any obligation or undertaking to
publicly release any updates or revisions to any forward-looking
statement contained herein (or elsewhere) to reflect any change in
the Company's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is
based.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160902005138/en/
Investor Relations:Institutional
InvestorsIn-Site Communications, Inc.Lisa Wilson,
212-452-2793Presidentlwilson@insitecony.comorIndividual InvestorsMZ North AmericaGreg Falesnik,
949-385-6449Senior Vice Presidentgreg.falensik@mzgroup.usorMedia
Relations:Pascale Communications, LLCAllison Potter,
412-228-1678Senior Account
Executiveallison@pascalecommunications.com
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Mar 2024 to Apr 2024
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Apr 2023 to Apr 2024